PL2043662T3 - Sposoby i kompozycje do leczenia choroby - Google Patents

Sposoby i kompozycje do leczenia choroby

Info

Publication number
PL2043662T3
PL2043662T3 PL07870731T PL07870731T PL2043662T3 PL 2043662 T3 PL2043662 T3 PL 2043662T3 PL 07870731 T PL07870731 T PL 07870731T PL 07870731 T PL07870731 T PL 07870731T PL 2043662 T3 PL2043662 T3 PL 2043662T3
Authority
PL
Poland
Prior art keywords
compositions
methods
treating disease
disease
treating
Prior art date
Application number
PL07870731T
Other languages
English (en)
Inventor
Thomas D Reed
Robert P Beech
Original Assignee
Intrexon Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Intrexon Corp filed Critical Intrexon Corp
Publication of PL2043662T3 publication Critical patent/PL2043662T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/711—Natural deoxyribonucleic acids, i.e. containing only 2'-deoxyriboses attached to adenine, guanine, cytosine or thymine and having 3'-5' phosphodiester links
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/0081—Purging biological preparations of unwanted cells
    • C12N5/0093—Purging against cancer cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/45—Transferases (2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0647—Haematopoietic stem cells; Uncommitted or multipotent progenitors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/70—Enzymes
    • C12N2501/72—Transferases [EC 2.]
    • C12N2501/724—Glycosyltransferases (EC 2.4.)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y204/00—Glycosyltransferases (2.4)
    • C12Y204/02—Pentosyltransferases (2.4.2)
    • C12Y204/02036—NAD(+)--diphthamide ADP-ribosyltransferase (2.4.2.36)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Oncology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Developmental Biology & Embryology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
PL07870731T 2006-07-26 2007-07-26 Sposoby i kompozycje do leczenia choroby PL2043662T3 (pl)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US82038106P 2006-07-26 2006-07-26
US88909507P 2007-02-09 2007-02-09
PCT/US2007/016747 WO2008073154A2 (en) 2006-07-26 2007-07-26 Methods and compositions for treating disease
EP07870731.2A EP2043662B1 (en) 2006-07-26 2007-07-26 Methods and compositions for treating disease

Publications (1)

Publication Number Publication Date
PL2043662T3 true PL2043662T3 (pl) 2016-03-31

Family

ID=39512236

Family Applications (1)

Application Number Title Priority Date Filing Date
PL07870731T PL2043662T3 (pl) 2006-07-26 2007-07-26 Sposoby i kompozycje do leczenia choroby

Country Status (16)

Country Link
US (3) US20100003226A1 (pl)
EP (1) EP2043662B1 (pl)
JP (1) JP2009544711A (pl)
KR (1) KR20090035011A (pl)
AU (1) AU2007332980A1 (pl)
CA (1) CA2658836C (pl)
DK (1) DK2043662T3 (pl)
ES (1) ES2553332T3 (pl)
HU (1) HUE027142T2 (pl)
IL (1) IL196638A (pl)
MX (1) MX2009000966A (pl)
NZ (1) NZ575075A (pl)
PL (1) PL2043662T3 (pl)
PT (1) PT2043662E (pl)
RU (1) RU2468820C2 (pl)
WO (1) WO2008073154A2 (pl)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013109944A1 (en) * 2012-01-18 2013-07-25 The Trustees Of The University Of Pennsylvania Methods for assessing risk for cancer using biomarkers
KR102165348B1 (ko) 2012-05-09 2020-10-14 캔텍스 파마슈티칼즈, 인크. 골수억제의 치료
WO2016133910A1 (en) 2015-02-17 2016-08-25 Cantex Pharmaceuticals, Inc. Treatment of cancers and hematopoietic stem cell disorders privileged by cxcl12-cxcr4 interaction
US20160243168A1 (en) * 2015-02-17 2016-08-25 Cantex Pharmaceuticals, Inc. Adoptive cell transfer methods
CA3004742A1 (en) 2015-11-11 2017-05-18 Intrexon Corporation Compositions and methods for expression of multiple biologically active polypeptides from a single vector for treatment of cardiac conditions and other pathologies
JP7051060B2 (ja) * 2017-05-09 2022-04-11 学校法人慶應義塾 脳腫瘍治療用細胞製剤

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5830686A (en) * 1994-01-13 1998-11-03 Calydon Tissue-specific enhancer active in prostate
EP0776218A2 (en) * 1994-03-15 1997-06-04 Prizm Pharmaceuticals, Inc. Heparin-binding growth factors for gene therapy and anterior eye disorders
WO2002060950A2 (en) * 1994-11-14 2002-08-08 Ludwig Institute For Cancer Research Flt4(vegfr-3) as a target for tumor imaging and anti-tumor therapy
AU710309B2 (en) * 1995-05-16 1999-09-16 Selective Genetics, Inc. Compositions containing nucleic acids and ligands for therapeutic treatment
EP0923387B1 (en) * 1996-06-24 2001-09-26 Selective Genetics, Inc. Heparin-coated medical devices for intravenous use containing heparin-binding growth factor conjugates
CN1303436A (zh) * 1998-02-19 2001-07-11 圣朱迪儿童研究医院 致敏和抑制人肿瘤细胞生长的组合物和方法
US7691370B2 (en) * 1998-10-15 2010-04-06 Canji, Inc. Selectivity replicating viral vector
WO2000075347A2 (en) * 1999-06-07 2000-12-14 Wolfgang Hillen Tet repressor-based transcriptional regulatory proteins
AU2001249315A1 (en) 2000-03-22 2001-10-03 Rheogene, Inc. Ecdysone receptor-based inducible gene expression system
US20040033600A1 (en) 2001-03-21 2004-02-19 Palli Subba Reddy Ecdysone receptor-based inducible gene expression system
WO2002014495A2 (en) * 2000-08-14 2002-02-21 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Enhanced homologous recombination mediated by lambda recombination proteins
US8105825B2 (en) 2000-10-03 2012-01-31 Intrexon Corporation Multiple inducible gene regulation system
DK1534738T3 (da) 2001-02-20 2012-10-01 Intrexon Corp Nye substitutionsmutantreceptorer og anvendelse heraf i et inducérbart genekpressionssystem på basis af en nuklear receptor
JP4328094B2 (ja) 2001-02-20 2009-09-09 イントレクソン・コーポレイション 新規置換突然変異体受容体および核受容体−ベースの誘導性遺伝子発現システムにおけるその使用
WO2002066614A2 (en) 2001-02-20 2002-08-29 Rheogene Holdings, Inc. Chimeric retinoid x receptors and their use in a novel ecdysone receptor-based inducible gene expression system
US9493540B2 (en) 2001-02-20 2016-11-15 Intrexon Corporation Ecdysone receptor/invertebrate retinoid X receptor-based inducible gene expression system
US6828102B2 (en) * 2001-11-20 2004-12-07 Albany Medical College Plasmids and methods for monitoring endonuclease digestion efficiency
EP1327688A1 (en) * 2002-01-14 2003-07-16 Vereniging Voor Christelijk Wetenschappelijk Onderwijs Adenoviruses with enhanced lytic potency
WO2004016791A1 (en) * 2002-08-01 2004-02-26 Evolva Ltd Methods of mixing large numbers of heterologous genes
US7785871B2 (en) 2002-10-09 2010-08-31 Intrexon Corporation DNA cloning vector plasmids and methods for their use
WO2004111074A2 (en) * 2003-05-30 2004-12-23 The Cleveland Clinic Foundation In vivo production of a clostridial neurotoxin light chain peptide
CA2436196A1 (en) * 2003-07-25 2005-01-25 Oncolytics Biotech Inc. Oncolytic virus for purging cellular compositions of cells of lymphoid malignancies
US7935510B2 (en) 2004-04-30 2011-05-03 Intrexon Corporation Mutant receptors and their use in a nuclear receptor-based inducible gene expression system
EP1751298A4 (en) 2004-05-18 2009-11-11 Intrexon Corp METHOD FOR DYNAMIC VECTOR ASSEMBLY OF DNA CLONING VECTOR PLASMIDES

Also Published As

Publication number Publication date
WO2008073154A3 (en) 2008-12-04
KR20090035011A (ko) 2009-04-08
HUE027142T2 (en) 2016-08-29
EP2043662A4 (en) 2010-04-14
RU2468820C2 (ru) 2012-12-10
CA2658836A1 (en) 2008-06-19
PT2043662E (pt) 2015-11-25
HK1129596A1 (en) 2009-12-04
EP2043662A2 (en) 2009-04-08
ES2553332T3 (es) 2015-12-07
US20150132265A1 (en) 2015-05-14
IL196638A (en) 2013-11-28
JP2009544711A (ja) 2009-12-17
CA2658836C (en) 2017-11-28
DK2043662T3 (en) 2015-12-14
MX2009000966A (es) 2009-03-05
IL196638A0 (en) 2009-11-18
US20170191027A1 (en) 2017-07-06
WO2008073154A2 (en) 2008-06-19
NZ575075A (en) 2011-10-28
US20100003226A1 (en) 2010-01-07
EP2043662B1 (en) 2015-09-09
AU2007332980A1 (en) 2008-06-19
RU2009103208A (ru) 2010-09-10

Similar Documents

Publication Publication Date Title
IL291175A (en) Compositions and methods for treating collagen-mediated diseases
IL257681A (en) Methods and compositions for the treatment of cancer
PL2578081T4 (pl) Kompozycje, sposoby i urządzenia do leczenia chorób wątroby
EP1959929A4 (en) COMPOSITIONS AND METHODS FOR TREATING DERMATOLOGICAL SUFFERING
IL197721A0 (en) Compositions and methods for diagnosing and treating cancer
PL2032166T3 (pl) Kompozycje i sposoby diagnozowania i leczenia nowotworów
IL193014A0 (en) Methods and compositions for treating schizophrenia
IL195619A0 (en) Compositions and methods for joininig non-conjoined iumens
IL186963A0 (en) Methods and compositions for treating pain
ZA200900140B (en) Methods and compositions for treating biofilms
EP2244690A4 (en) METHOD AND COMPOSITIONS FOR THE TREATMENT OF SKIN DISEASES AND DRESSES
IL198723A0 (en) Methods and compositions for therapeutic treatment
HUP0700369D0 (en) Pharmaceutical compositions and method for treating schizofrenia
EP1890712A4 (en) COMPOSITIONS AND METHODS FOR TREATING PAIN
GB0718918D0 (en) Compositions and methods for treating skin conditions
IL196638A0 (en) Methods and compositions for treating disease
GB0620695D0 (en) Composition and methods for the treatment of nurdegenerative disease
EP2094279A4 (en) METHOD AND COMPOSITIONS FOR THE TREATMENT OF INFLUENZA
GB0618309D0 (en) Compositions and methods for the treatment of disease
ZA200807049B (en) Compositions and methods for treating collagen-mediated diseases
GB0507963D0 (en) Composition and method for treating disease
GB0522732D0 (en) Composition and method for treating disease
GB0620693D0 (en) Composition and methods for the treatment of degenerative disease